Artificial Intelligence firm Bioptimus achieves $76 million funding threshold, announcing the impending release of their AI foundation model.
Bioptimus, a pioneering AI foundation model company, has announced the launch of its first universal AI model for biology, H-Optimus-0. This groundbreaking model, which has already been claimed as the world's largest foundation model for pathology, has secured a funding of $76 million.
The funding round was led by Cathay Innovation, with participation from Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, Boom Capital Ventures, Pomifer Capital, Sunrise, angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf.
According to Jean-Philippe Vert, co-founder and CEO of Bioptimus, the model they are building will empower researchers in the pharmaceutical industry to simulate complex biology, predict disease outcomes, and design therapies with unprecedented precision.
A Transformative Tool for Medical, Biotech, and Cosmetic Industries
The universal AI model developed by Bioptimus is expected to have significant impacts on various industries. In the medical industry, it could accelerate breakthroughs in drug discovery and personalized medicine by enabling comprehensive biological modeling and more precise insights into biological processes.
In the biotech sector, the model is expected to facilitate innovative development pipelines, improve biological data integration, and enable new applications in synthetic biology and bioengineering. Meanwhile, in the cosmetic industry, it could likely advance product development by enhancing understanding of biological interactions at cellular and molecular levels, leading to safer and more effective cosmetic formulations.
Integrating Data Across Scales and Modalities
Bioptimus's approach integrates data across multiple scales (molecules, cells, tissues, organisms) and modalities (imaging, genetics, etc), enabling a holistic view of biology. This holistic approach is expected to pave the way for groundbreaking innovations across industries, from pharmaceuticals to biotechnology and beyond.
The funding will be used to build the world's first universal AI foundation model for biology, enabling Bioptimus to enhance its multi-modal AI platform, integrating even more diverse data sources and therapeutic areas. The funding will also be used to expand critical datasets to further refine and validate Bioptimus's models.
A Step Towards Unifying Biological Data and Modeling
Bioptimus's goal is to revolutionize research and innovation across the medical, biotech, and cosmetic industries, among others. By redefining biological research and addressing the siloed nature of biological understanding, Bioptimus is forging strategic partnerships with pharmaceutical and biotech companies to drive biological discoveries in ways we are only beginning to imagine.
The studies conducted by Harvard Medical School's HEST program and the University of Leeds have highlighted the model's ability to predict gene expression from morphology and to subtype ovarian cancer with exceptional accuracy. H-Optimus-0 has outperformed all other pathology models in independent benchmarks, demonstrating its potential to unlock limitless possibilities across many other industries.
Jacky Abitbol, Partner at Cathay Innovation, stated that Bioptimus is at the forefront of transforming biological research, leveraging AI to break down silos and unlock the full complexity of biology. The funding will enable Bioptimus to continue its mission of unifying biological data and modeling, with broad expected applications in medical, biotech, and cosmetic fields to fuel innovation and discovery.
Read also:
- Elon Musk Acquires 26,400 Megawatt Gas Turbines for Powering His AI Project, Overlooks Necessary Permits for Operation!
- U Power's strategic collaborator UNEX EV has inked a Letter of Intent with Didi Mobility to deploy UOTTA(TM) battery-swapping electric vehicles in Mexico.
- Global Gaming Company, LINEUP Games, Moves Into Extensive Global Web3 Multi-Platform Gaming Network
- Toyota strikes a deal in Shanghai for a solely owned Lexus electric vehicle production plant.
